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Abstract
There is a large body of scientific evidence suggesting that 3,39-Diindolylmethane (DIM), a compound derived from the
digestion of indole-3-carbinol, which is abundant in cruciferous vegetables, harbors anti-tumor activity in vitro and in vivo.
Accumulating evidence suggests that AMP-activated protein kinase (AMPK) plays an essential role in cellular energy
homeostasis and tumor development and that targeting AMPK may be a promising therapeutic option for cancer treatment
in the clinic. We previously reported that a formulated DIM (BR-DIM; hereafter referred as B-DIM) with higher bioavailability
was able to induce apoptosis and inhibit cell growth, angiogenesis, and invasion of prostate cancer cells. However, the
precise molecular mechanism(s) for the anti-cancer effects of B-DIM have not been fully elucidated. In the present study, we
investigated whether AMP-activated protein kinase (AMPK) is a molecular target of B-DIM in human prostate cancer cells.
Our results showed, for the first time, that B-DIM could activate the AMPK signaling pathway, associated with suppression of
the mammalian target of rapamycin (mTOR), down-regulation of androgen receptor (AR) expression, and induction of
apoptosis in both androgen-sensitive LNCaP and androgen-insensitive C4-2B prostate cancer cells. B-DIM also activates
AMPK and down-regulates AR in androgen-independent C4-2B prostate tumor xenografts in SCID mice. These results
suggest that B-DIM could be used as a potential anti-cancer agent in the clinic for prevention and/or treatment of prostate
cancer regardless of androgen responsiveness, although functional AR may be required.
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Introduction
AMP-activated protein kinase (AMPK) is expressed in all
eukaryotic cells and is a critical enzyme that plays an essential
role in cellular energy homeostasis, as well as controlling
processes related to tumor development including cell cycle
progression, cell proliferation, protein synthesis, and survival.
Therefore, as an anti-cancer target, AMPK has received
intensive attention in recent years. Mammalian AMPK is a
trimeric serine/threonine protein kinase composed of a catalytic
a subunit and two regulatory subunits, b and c. AMPK is
activated through phosphorylation of Thr-172 on the a subunit
by an energy-depleting stress, such as increased ratios of AMP/
ATP [1] and ADP/ATP [2], or stimulated by cellular kinases
including liver kinase B1 (LKB1) [3–4] and calmodulin-depen-
dent protein kinase kinase (CaMKK) [5]. Once activated, AMPK
plays two major functions, metabolic and non-metabolic. In the
regulation of metabolic process, AMPK phosphorylates serine
moieties in many target proteins and results in switching on of
catabolic pathways to activate ATP-generating processes includ-
ing the uptake and oxidation of glucose and fatty acids, and
switching off of anabolic pathways including protein, fatty acid
and cholesterol syntheses, which consume ATP [6]. Regarding
non-metabolic functions of AMPK, activation of AMPK can
induce cell cycle arrest and inhibit cell proliferation and protein
synthesis in malignant cells through multiple mechanisms such as
the accumulation of tumor suppressor factor p53 and the cyclin-
dependent kinase inhibitors p21 and p27 [7], as well as down-
regulation of the mTOR pathway [8–9]. Extensive research
supports the role of AMPK in cancer prevention and therapeu-
tics, suggesting that targeting AMPK may be a promising option
for cancer treatment.
To that end, metformin, an anti-diabetic drug, has been shown
to activate AMPK, raising a hypothesis that metformin may
reduce the risk of cancer in patients with type 2 diabetes through
activation of the AMPK pathway [10]. Indeed, reports from
clinical studies have demonstrated that diabetic patients treated
with metformin had a significantly lower rate of cancer incidences
and cancer-related mortality compared with patients exposed to
other anti-diabetic medicines [10–12]. Pre-clinical studies have
also shown that metformin not only inhibits growth of cultured
cancer cells [13–14] and tumors in mice [15], but also selectively
targets cancer stem cells [16].
Besides metformin, some natural compounds, including
quercetin, genistein [17], capsaicin, EGCG [18], and curcumin
[19], have been shown to have anticancer effects associated with
activation of the AMPK signaling pathway. In fact, natural
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products have been the most productive source of leads for the
development of anti-cancer drugs. According to the literature,
approximately 73% of anticancer drugs were discovered from
natural origins or derived from natural compounds over the past
half a century [20]. The natural compound indole-3-carbinol
(I3C), which is found at relatively high levels in cruciferous
vegetables such as broccoli and cabbage, and its dimer 3,39-
diindolylmethane (DIM) have shown anti-tumor activity in vitro
and in vivo [21–22]. Recently, we reported that a formulated
DIM (BR-DIM, obtained from BioResponse Nutrients, LLC.,
Boulder, Colorado, hereafter abbreviated as B-DIM), showed
approximately 50% higher bioavailability in vivo [23] compared
with DIM. B-DIM induced apoptosis and inhibited cell growth,
angiogenesis, and invasion of prostate cancer cells, which is
associated with regulation of Akt, NF-kB, VEGF and AR
signaling pathways [24–25]. In addition, recent results have
shown that B-DIM treatment of prostate cancer cells in vitro or B-
DIM intervention in patients with prostate cancer led to the
nuclear exclusion of AR associated with activation of miR-34a
[24]. However, the precise molecular mechanism(s) by which B-
DIM plays its anti-cancer and cancer-preventive roles have not
been fully elucidated; more specifically, it has not been reported
whether the biological activity of B-DIM is related to induction
of AMPK signaling.
Therefore, in the current study, we investigated the effects of B-
DIM on AMPK signaling and its related downstream targets in
both androgen-sensitive LNCaP and androgen-insensitive C4-2B
prostate cancer cells containing functional AR. Our results
showed, for the first time, that B-DIM could function as an
AMPK activator. Activation of AMPK by B-DIM resulted in the
down-regulation of AR and prostate-specific antigen (PSA)
expression, and caused induction of cell apoptosis, suppression of
mTOR pathway, and inhibition of prostasphere formation in
human prostate cancer cells in vitro and in vivo. Our findings also
demonstrated that the AMPK pathway is one of the novel
molecular targets of B-DIM for its anti-cancer effects against
human prostate cancer.
Methods
Cell Culture, Protein Extraction, and Western Blot Assay
Human prostate cancer C4-2B (obtained from Professor Leland
Chung, Emory University, School of Medicine, Atlanta, GA; and
currently at Cedars-Sinai, Los Angeles, CA) and LNCaP
(American Type Culture Collection Manassas, VA, USA) cells
were grown in RPMI 1640 medium (Invitrogen, Carlsbad, CA)
supplemented with 10% fetal calf serum (FCS), 100 mg/ml
streptomycin, 100 units/ml penicillin, and 2 mM glutamine, in a
humidified incubator with 5% CO2 and 95% air at 37uC. A whole
cell extract was prepared as previously described [26]. For
Western blot analysis, an equal amount of protein from each cell
extract was subjected to denaturing polyacrylamide gel electro-
phoresis (SDS-PAGE) and transferred to nitrocellulose mem-
branes. Individual membranes were probed with indicated
antibodies. Immunoreactive bands were developed using horse-
radish peroxidase conjugated secondary antibodies and Super-
Signal WestPico chemiluminescent substrate (Pierce) and visual-
ized using X-ray film.
Prostasphere Formation Assay
Prostasphere formation assay was performed to assess the
capacity of cancer stem cell self-renewal following our published
procedure [27]. Briefly, single cell suspensions of C4-2B cells were
thoroughly suspended and plated in ultra low adherent-wells of 6-
well plates (Corning, Lowell, MA) at 1,000 cells/well in 1.5 ml of
sphere formation medium (1:1 DMEM/F12 medium supplement-
ed with 50 units/ml penicillin, 50 mg/ml streptomycin, B-27, and
N-2). One milliliter of sphere formation medium was added every
3 days. After 6 days of incubation with different concentrations of
B-DIM or metformin (as a control), the formed spheres were
collected by centrifugation at 3006g for 5 minutes and prosta-
sphere numbers were counted under an inverted phase-contrast
microscope. The proportion of sphere-generating cells was
calculated by dividing the number of cells seeded by the number
of prostaspheres.
Experimental Animals
Male homozygous CB-17 SCID mice (4–5 weeks old) were
purchased from Taconic Farms (Germantown, NY). The mice
were housed and maintained under sterile conditions in facilities
accredited by the American Association for the Accreditation of
Laboratory Animal Care and in accordance with current
regulations and standards of the U.S. Department of Agriculture,
U.S. Department of Health and Human Services, and NIH. The
mice were used in accordance with Animal Care and Use
Guidelines of Wayne State University under a protocol approved
by the Wayne State University Animal Care and Use Commit-
tee. Mice received Lab Diet 5021 (Purina Mills, Inc., Richmond,
IN).
Human Bone and Implantation of Tumor Cells
Human male fetal bone tissue was obtained by a third party
nonprofit organization (Advanced Bioscience Resources, Alame-
da, CA), and written informed consent was obtained from the
donor family, consistent with regulations issued by each state
involved and the federal government. After one week of
acclimatization, the mice were implanted with a single human
fetal bone fragment as described previously [28–29]. C4-2B cells
were harvested from subconfluent cultures after a brief exposure
to 0.25% trypsin and 0.2% EDTA. Trypsinization was stopped
by adding a medium containing 10% FBS. The cells were
washed once in serum-free medium and resuspended. Only
suspensions consisting of a single cell with .90% viability were
used for the injections. Cells (16106) in 20-mL serum-free RPMI
medium were injected intraosseously by insertion of a 27-gauge
needle and Hamilton syringe through the mouse skin directly
into the marrow surface of the previously implanted bone. In
our previous experience with this model, we found a tumor
uptake rate of .95% compared to skin xenograft wherein the
tumor uptake rate was comparatively less with prolonged
latency period. As soon as the majority of the bone implants
began to enlarge (now called a ‘‘bone tumor’’) as determined by
caliper measurements (30th day after cancer cell injection), mice
were randomized into the following treatment groups (n = 7): (a)
untreated control; (b) only B-DIM, 5 mg/mice fed everyday
orally by gavage for 4 weeks since the initiation of therapy. The
volume of the bone tumor in each group was determined by
twice weekly caliper measurements. The body weight of mice in
each group was also measured. All mice were euthanized one
day after the last dose of B-DIM treatment (5 weeks) because
large tumors were formed in the control mice, which required
termination, and their final body weight and tumor volume
were recorded. On autopsy, the tumor was neatly excised, freed
of any extraneous adhering tissue, and part of the tissue was
fixed in formalin and embedded in paraffin for immunostaining
and H&E staining for confirming the presence of tumor.
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Results
B-DIM Activates AMPK Signaling in Human Prostate
Cancer Cells
We assessed whether the AMPK signaling pathway could be
one of the molecular targets of B-DIM in both androgen-
insensitive C4-2B (Fig. 1A) and androgen-sensitive LNCaP
(Fig. 1B) prostate cancer cells. Both cell lines were treated with
different concentrations of B-DIM for 3 hours, and cell lysates of
the treated cells were analyzed by Western blot to measure the
levels of phosphor-AMPKa (T172), an active form of AMPK
protein, as well as some downstream target proteins. The results
showed that the level phosphor-AMPKa in both prostate cancer
cell lines treated with B-DIM increased in a dose-dependent
manner (Fig. 1A, B). As a control, the total AMPK protein levels
remained relatively unchanged (Fig. 1A, B). Both regulatory-
associated protein of mTOR (Raptor) and acetyl-CoA carboxylase
(ACC) are direct downstream substrates of AMPK, as activated
AMPK is able to phosphorylate Raptor protein on serine residue
792 [8] and ACC protein on serine residue 79 [30–31]. Treatment
with B-DIM resulted in increased levels of phosphor-Raptor
(S792) and phosphor-ACC (S79) in the treated cells (Fig. 1A, B),
further supporting that B-DIM is an AMPK activator. mTOR is a
downstream signaling pathway of AMPK, and activation of
AMPK can inhibit the mTOR signaling pathway [32]. Our data
also revealed that activation of AMPK by B-DIM could suppress
the mTOR pathway, as measured by decreased protein level of
phosphor-mTOR (Fig. 1A, B), demonstrating, for the first time,
the functionality of B-DIM as an AMPK activator in both AR-
sensitive and AR-insensitive prostate cell lines. The inactivation of
mTOR by B-DIM is consistent with our previously published
report [33].
Activation of AMPK by B-DIM at Early Hours is Associated
with Subsequent Down-regulation of AR and PSA Protein
Expression and Induction of Apoptosis in Human
Prostate Cancer Cells
The results displayed above show that B-DIM harbors AMPK-
activating property. We then investigated whether activation of
AMPK by B-DIM could result in apoptotic cell death and inhibit
the expression of prostate cancer signature proteins, such as AR
and PSA. We showed previously that activation of AMPK
signaling by B-DIM is an early event that occurs as early as three
hour-treatment (the upper panel of Fig. 1A, B). We found that
further treatment of C4-2B and LNCaP cells with B-DIM for up to
24 hours significantly decreased the expression levels of AR and
PSA in a dose-dependent manner, and also resulted in apoptotic
cell death as measured by PARP cleavage (the lower panel of
Fig. 1A, B). These data suggest that activation of the AMPK
signaling pathway is one of the major targets of B-DIM leading to
the induction of apoptotic cell death of prostate cancer cells.
Activation of AMPK by B-DIM can be Blocked by an AMPK
Inhibitor
Compound C was developed as a selective inhibitor of AMPK
[34]. We hypothesized that if AMPK is an essential molecular
target of B-DIM, co-treatment with Compound C should
attenuate or block the effects of B-DIM on prostate cancer cells.
To test this hypothesis, prostate cancer C4-2B and LNCaP cells
were pre-treated with either 20 mM of Compound C or DMSO
for 6 hours and then co-treated with B-DIM at two concentrations
for additional 3 hours. The immunoblotting results showed that in
both prostate cancer cell lines treated with B-DIM alone, AMPK
signaling was activated as measured by a dose-dependent increase
in the phosphorylation of AMPKa (T172) and the phosphoryla-
tion of Ser79-ACC (Fig. 2), a direct substrate of AMPK that is
widely used as a detector of AMPK activation [35–37]. However
the protein levels of phosphor-AMPKa and phosphor-ACC were
dramatically decreased in cells pre-treated and co-treated with
Compound C (Fig. 2), suggesting that B-DIM-activated AMPK
can be blocked by an AMPK inhibitor.
B-DIM Enhances AR Suppressing-effect of Anti-AR Drug
Casodex
One of the current treatment strategies for advanced prostate
cancer is to suppress AR function by castration and anti-
androgens. Casodex is an anti-androgen drug clinically used for
patients with metastatic/advanced stage prostate cancer, and
works by binding and preventing the activation of the AR. Our
previous studies have shown that B-DIM is able to inhibit AR
expression in prostate cancer cells [24]. We further hypothesized
that the combination of B-DIM with casodex may have a
synergetic effect on the inhibition of AR expression and induction
of apoptosis in prostate cancer cells, which may be associated with
the activation of AMPK. To test this hypothesis we co-treated both
prostate cancer cell lines with 100 mM of casodex and 40 mM of B-
DIM for 24 hours, and treatment with each agent alone served as
controls. The data show that co-treatment of C4-2B and LNCaP
cells with casodex and B-DIM significantly decreased the
expression level of AR and increased apoptosis-associated PARP
cleavage compared to each treatment alone, and the synergetic or
additive effect was accompanied by increased AMPK activation
(Fig. 3).
Both B-DIM and Metformin Significantly Inhibits
Prostasphere Formation
Tumor stem cells have the characteristics of forming tumor-
spheres. It has been shown that metformin could inhibit cancer
stem cell growth, associated with AMPK activation [16]. In order
to test whether B-DIM, which functions as an AMPK activator
(Fig. 1, 2, 3) could target cancer stem-like cells and inhibit
prostasphere formation, C4-2B cells were treated with different
concentrations of B-DIM for 6 days in ultra-low adherent wells of
6-well plates. Treatment with metformin served as a control. The
results showed that B-DIM inhibited prostasphere formation by
29% and 90% at treatment concentrations of 10 mM and 25 mM,
respectively (Fig. 4), which is consistent with our previous findings
[27]. The data demonstrate that B-DIM may possess the ability to
suppress tumor stem-like cells in prostate cancer through
activation of the AMPK pathway.
B-DIM Activates AMPK and Down-regulates AR in
Androgen Independent C4-2B Prostate Tumor
Xenografts in SCID Mice
The above results from our in vitro studies clearly showed that
the AMPK signaling pathway is one of the novel molecular targets
of B-DIM in prostate cancer cells. To confirm this finding in vivo,
we designed and used the experimental bone metastasis animal
model (see Materials and Methods) that mimics bone metastasis of
human prostate cancer. We found that B-DIM treatment in vivo
inhibited C4-2B tumor growth within the bone microenvironment
to some extent (20%; data not shown). The tumor tissues were
removed and analyzed by immunohistochemistry using anti-
phosphor-AMPKa, phosphor-ACC and AR antibodies. The
results showed that p-AMPK- and p-ACC-positive cell popula-
tions increased significantly, while AR-positive cells decreased
B-DIM Activates AMPK Pathway in Prostate Cancer
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greatly in the tumors treated with B-DIM compared to the control
(Fig. 5). These findings confirm that B-DIM is able to activate the
AMPK pathway in vivo, associated with its anti-cancer activity.
Discussion
The search for new antitumor drugs from natural sources is one
of the most promising approaches for cancer prevention and
Figure 1. B-DIM activates the AMPK pathway, resulting in inhibition of AR and PSA expression and induction of apoptosis in
prostate cancer cells. Human prostate cancer C4-2B (A) or LNCaP (B) cells were treated with indicated concentrations of B-DIM for 3 hours to
measure protein levels of phosphor-AMPKa, AMPKa, phosphor-Raptor, phosphor-ACC, phosphor-mTOR, or for 24 hours to measure protein levels of
AR, PSA or PARP cleavage by Western blot analysis. Measurement of b-actin served as loading controls. The numbers underneath the Western results
of phosphor-AMPKa indicate quantified normalized phosphor-AMPKa and b-actin ratios.
doi:10.1371/journal.pone.0047186.g001
Figure 2. AMPK inhibitor Compound C can block AMPK
activation by B-DIM in prostate cancer cells. Prostate cancer C4-
2B and LNCaP cells were pre-treated with 20 mM of AMPK inhibitor
Compound C (CC) for 6 hours, followed by co-treatment with indicated
concentrations of B-DIM for 3 hours. Cell extracts of the treated cells
were immunoblotted for anti-phosphor-AMPKa, phosphor-ACC or b-
actin antibodies.
doi:10.1371/journal.pone.0047186.g002
Figure 3. B-DIM enhances the effects of AR inhibitor casodex in
prostate cancer cells, associated with increased activation of
AMPK. Prostate cancer C4-2B and LNCaP cells were treated with
100 mM of casodex, 40 mM of B-DIM alone or a combination of casodex
and B-DIM for 24 hours, followed by Western blot analysis using anti-
phosphor-AMPKa, AR, PARP or b-actin antibodies.
doi:10.1371/journal.pone.0047186.g003
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therapy. We have been studying formulated 3,39-Diindolyl-
methane (B-DIM) and showed that B-DIM can induce apoptosis
and inhibit cell growth, angiogenesis, and invasion of prostate
cancer cells by regulating NF-kB, Akt and AR signaling pathways
[24–25]. However, the precise molecular mechanism(s) by which
B-DIM elicit its anti-cancer effects on human prostate cancer have
not been fully elucidated. In this study, we discovered that AMPK
is one of the direct molecular targets of B-DIM in prostate cancer
cells in vitro and in vivo.
The AMPK signaling pathway has recently become an
important focus of interest in cancer prevention and therapy.
Bowker et al. investigated the incidence of cancer in 10,309
diabetic patients treated with insulin, metformin or sulfonylureas
for a period of 5 years. They reported that patients treated with
metformin had a significantly lower rate of cancer-related
mortality compared with patients exposed to other anti-diabetic
medicines [12]. The major anti-cancer mechanism of metformin
was associated with activation of AMPK signaling [34]. Activation
of AMPK inhibits energy consuming pathways, protein synthesis
and cell proliferation, through suppression of the mTOR pathway
via tuberous sclerosis 2 protein (TSC-2) [38]. Hirsch H et al.
reported that metformin selectively targets cancer stem cells and
inhibits tumor growth in mouse models mediated by activation of
the AMPK pathway [16]. It has been reported that some natural
compounds including genistein (rich in soy bean), EGCG
(abundant in green tea), and capsaicin (from hot pepper) are able
to activate the AMPK pathway [17]. Discovery of more AMPK
activators from natural sources is becoming an attractive approach
to cancer prevention and therapy.
Our current findings show that B-DIM can activate AMPK
signaling as early as three hours in both androgen-sensitive
LNCaP and androgen-insensitive C4-2B prostate cancer cells,
measured by: (i) increased protein levels of phosphor-AMPKa
Figure 4. Treatment with B-DIM or metformin inhibits prostasphere-forming ability. C4-2B cells were treated with indicated doses of B-
DIM (A, B) for 6 days. Treatment with different concentrations of metformin served as controls (C, D). After 6 days, prostasphere numbers were
counted under the microscope and the proportion of sphere-generating cells was calculated by dividing the number of cells seeded by the number
of prostaspheres (A, C). Prostaspheres from C4-2B cells treated with B-DIM (B) or metformin (D) were photographed and the results showed that 10
and 25 mM of B-DIM significantly reduced size and numbers of prostaspheres. n = 6, * P,0.05, ** P,0.01.
doi:10.1371/journal.pone.0047186.g004
Figure 5. B-DIM activates AMPK signaling and inhibits AR
expression in prostate tumor xenograft tissues. ICR SCID mice
were implanted with C4-2B cells and treated with 5 mg/mouse of B-
DIM by oral gavages daily for 4 wks. Tumor tissues were analyzed by
immunohistochemistry using anti-phosphor-AMPKa (T172), phosphor-
ACC (S79) or AR antibodies. The stained sections were visualized under
the microscope (4006amplification). Unlike solvent-treated control,
mice treated with B-DIM presented with activation of AMPK and
significant loss of AR in tumor sections.
doi:10.1371/journal.pone.0047186.g005
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(T172), (ii) increased levels of phosphorylated ACC on serine
residue 79 [30–31], (iii) increased protein levels of phosphor-
Raptor (S792), which is a direct target of AMPK and an mTOR
binding partner and inhibitor [8], and (iv) decreased levels of
phosphor-mTOR (Fig. 1). Consequences of AMPK activation by
B-DIM appear to be mediated through inhibition of AR and PSA
expression, leading to the induction of apoptosis upon further
treatment for an additional 21 hours (Figs. 1, 6). AMPK activation
by B-DIM could be blocked by pre-treatment with Compound C,
an AMPK inhibitor, in the prostate cancer cells (Fig. 2).
The androgen receptor (AR) is a critical factor for prostate
cancer development and progression. Prostate cancer is dependent
on androgen stimulation mediated by AR, and AR even plays an
important role in cancer development and drug-resistance in
androgen-independent prostate cancer cells. Alternative mecha-
nisms of AR activation in androgen-independent prostate cancer
are proposed through other signaling pathways, including ERKs,
Akt, b-catenin and caveolin [39–41]. Therefore suppression of AR
is one of the therapeutic strategies for prostate cancer patients.
Casodex is an anti-androgen drug clinically used for patients in
metastatic/advanced stage. Any natural compounds that could
enhance the efficacy of casodex have potential therapeutic benefit
in the clinic. We showed in the present study that co-treatment of
cells with casodex and B-DIM led to a significant increase in
phosphor-AMPKa and suppressed AR expression in prostate
cancer cells (Fig. 3), demonstrating a novel mechanism for synergy
of anti-AR therapy.
Prostate cancer tissue contains a rare population of multi-potent
cancer stem cells with the capacity to self-renew. These prostate
cancer stem cells could be enriched and measured by a colony
formation assay in three-dimensional cultures, referred to as
prostasphere formation. Prostate cancer cells with stem cell
characteristics possess the ability to form prostaspheres from single
cells as a condition for self-renewing in non-adherent culture
conditions [42]. To determine if B-DIM could target prostate
stem/stem-like cells, we tested it in prostasphere formation assays.
The result showed that after six-day incubation of C4-2B cells with
different doses of B-DIM, not only were numbers of formed
prostaspheres significantly decreased, but the size of prostaspheres
was reduced as well (Fig. 4). The findings from the in vitro studies
were further confirmed by the immunohistochemical results from
tumor tissues of prostate cancer xenografts treated with B-DIM
(Fig. 5). Positive cell populations stained with phosphor-AMPK or
phosphor-ACC were significantly increased, while AR-positive
cells were reduced in the B-DIM treated tumor tissue (Fig. 5).
In summary, the present study provides the first evidence that
the AMPK signaling pathway is one of the molecular targets of B-
DIM for its anti-cancer activity. Activation of AMPK by B-DIM
Figure 6. Schematic diagram showing the various mechanisms associated with inhibition of tumor growth and induction of
apoptosis by B-DIM.
doi:10.1371/journal.pone.0047186.g006
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results in the suppression of its downstream target mTOR, down-
regulation of AR expression and induction of apoptosis in both
androgen-sensitive LNCaP and androgen-insensitive C4-2B pros-
tate cancer cells (Fig. 6). Activation of AMPK by B-DIM was also
observed in treated prostate tumors. Our findings demonstrate
that B-DIM could be used as a potential agent in the clinic for the
prevention and/or treatment of prostate cancer regardless of
androgen responsiveness of the cells.
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